Experimental group:paromlimab and Tuvonralimab Injection:5mg/kg, on day 1 , day 21 of each cycle

A Prospective, Open-label, Exploratory Clinical Study of Iparomlimab and Tuvonralimab Injection +- TKI Agents in Advanced Hepatocellular Carcinoma Patients Previously Treated with Immune Checkpoint Inhibitors

An Open-label, Single-arm, Single-center Clinical Study of Iparomlimab and Tuvorralimab (QL1706) in Combination with Lenvatinib as First-line Treatment for Hepatocellular Carcinoma (HCC)